CCDC175

Across TCGA pan-cancer cohorts, CCDC175 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated CCDC175 data layer compared with 2 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CCDC175 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC175 expression acts as an unfavorable survival marker, although some lineages such as PAAD and BRCA show a favorable association.

LIHC, PAAD, and THCA are the cancer types where CCDC175 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	III,IV	0.290	0.667	<.001	99	view →
PAAD	OS	Median	All	0.584	0.295	<.001	85	view →
THCA	OS	Tertile	III,IV	0.543	0.941	<.001	62	view →
LGG	DFS	Median	All	0.660	0.804	<.001	52	view →
BRCA	OS	Median	III,IV	0.968	0.840	<.001	52	view →
CESC	DFS	Quartile	II,III,IV	0.638	0.824	.009	36	view →
STAD	OS	Quartile	All	0.301	0.609	.017	25	view →
LUSC	OS	Quartile	III,IV	0.515	0.709	.011	17	view →
SCLC	DFS	Median	II,III,IV	0.598	0.321	.008	16	view →
DLBC	OS	Tertile	II,III,IV	0.340	1.000	.023	15	view →
UCS	DFS	Tertile	IV	0.874	0.296	.024	12	view →
BLCA	OS	Tertile	All	0.822	0.344	.038	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

CCDC175–LIHC (OS)

Open the LIHC breakdown →